San Francisco Sentry Investment Group’s Novo Nordisk NVO Stock Holding History

San Francisco Sentry Investment Group’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-19,240	Closed	-$649K	–	727
2021 Q1	$649K	Hold	19,240	–	–	0.28%	99
2020 Q4	$672K	Hold	19,240	–	–	0.32%	86
2020 Q3	$668K	Hold	19,240	–	–	0.34%	77
2020 Q2	$630K	Buy	+19,240	New	+$614K	0.33%	80
2018 Q2	–	Sell	-88	Closed	-$2K	–	835
2018 Q1	$2K	Hold	88	–	–	﹤0.01%	860
2017 Q4	$2K	Hold	88	–	–	﹤0.01%	852
2017 Q3	$2K	Buy	+88	New	+$1.99K	﹤0.01%	856
2014 Q2	–	Sell	-12,000	Closed	-$274K	–	650
2014 Q1	$274K	Hold	12,000	–	–	0.09%	176
2013 Q4	$222K	Hold	12,000	–	–	0.08%	184
2013 Q3	$203K	Hold	12,000	–	–	0.08%	188
2013 Q2	$186K	Buy	+12,000	New	+$200K	0.07%	186

Other funds holding NVO

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $146B AUM 55.73% 1-Year Est. Return

Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return

San Francisco Sentry Investment Group's NVO Position: Q2 2021 in Review

San Francisco Sentry Investment Group sold out of Novo Nordisk (NVO) in Q2 2021, closing a stake of 19,240 shares — an estimated $649K sold.

San Francisco Sentry Investment Group first reported a position in NVO in Q2 2013 and held it in 11 quarters. The position peaked at $672K in Q4 2020. 736 funds tracked by Wall St. Rank hold NVO as of Q2 2021.

San Francisco Sentry Investment Group reported no remaining Novo Nordisk position as of Q2 2021 after selling out during the quarter.
San Francisco Sentry Investment Group sold 19,240 Novo Nordisk shares in Q2 2021, an estimated $649K.
San Francisco Sentry Investment Group first reported a position in Novo Nordisk in Q2 2013 and held it in 11 quarters.
San Francisco Sentry Investment Group's Novo Nordisk position peaked at $672K in Q4 2020.
736 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2021.

Based on San Francisco Sentry Investment Group's 13F filing for Q2 2021, filed 2 Aug 2021.